Siddharth Bhansali, MD
Interventional Cardiology · New Orleans, LANPI 1912999046
Payments from drug & device makers
Across 241 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$715
- Johnson & Johnson$596
- Amgen$562
- E.r. Squibb & Sons, L.L.C.$398
- Merck$370
- AstraZeneca$368
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,88799%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $715 |
| Johnson & Johnson | 34 | $596 |
| Amgen | 26 | $562 |
| E.r. Squibb & Sons, L.L.C. | 16 | $398 |
| Merck | 21 | $370 |
| AstraZeneca | 20 | $368 |
| Esperion Therapeutics, Inc. | 16 | $297 |
| Sanofi-aventis U.S. LLC | 9 | $194 |
| Novo Nordisk | 8 | $170 |
| Pfizer | 9 | $149 |
| Medtronic | 1 | $139 |
| Boehringer Ingelheim | 7 | $131 |
| Pacira Pharmaceuticals Incorporated | 1 | $123 |
| Lexicon Pharmaceuticals, Inc. | 6 | $117 |
| Edwards Lifesciences | 5 | $115 |
| Inari Medical, Inc. | 1 | $101 |
| Abiomed | 2 | $100 |
| Abbott | 4 | $73 |
| Boston Scientific | 2 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Tactile Systems Technology Inc | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $16 |
| Medicure Pharma Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$202
- COREVALVE EVOLUT R$139
- CAMZYOS$126
- EXPAREL$123
- Repatha$121
How this compares
$4,922 in reported general payments places this provider in the 25th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 384 | $381,156 |
| XareltoRivaroxaban | 274 | $313,375 |
| VyndamaxTafamidis | 11 | $246,892 |
| EntrestoSacubitril/Valsartan | 219 | $231,252 |
| JardianceEmpagliflozin | 185 | $189,936 |
| OzempicSemaglutide | 96 | $115,395 |
| MounjaroTirzepatide | 85 | $108,994 |
| Repatha SureclickEvolocumab | 67 | $68,351 |
| NexletolBempedoic Acid | 80 | $59,356 |
| FarxigaDapagliflozin Propanediol | 62 | $42,283 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $29,949 |
| MultaqDronedarone Hcl | 31 | $28,515 |
| JanuviaSitagliptin Phosphate | 18 | $24,051 |
| TrulicityDulaglutide | 19 | $23,341 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $16,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $149 | $628,047395 claims |
| Johnson & JohnsonXarelto | $596 | $313,375274 claims |
| NovartisEntresto | $715 | $231,252219 claims |
| Boehringer IngelheimJardiance | $131 | $189,936185 claims |
| Novo NordiskOzempic | $170 | $115,39596 claims |
| MerckJanumet, Januvia, Verquvo, Janumet Xr | $370 | $78,93384 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $297 | $72,46799 claims |
| AstraZenecaFarxiga | $368 | $42,28362 claims |
| Sanofi-aventis U.S. LLCMultaq | $194 | $28,51531 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13 | $8,18413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in New Orleans
- Stephen RameeNew Orleans$1.5M
- James JenkinsNew Orleans$1.2M
- Rajan PatelNew Orleans$633K
- Jose Tafur SotoNew Orleans$419K
- Anand IrimpenNew Orleans$100K
- George YousefNew Orleans$99K
- Jose WileyNew Orleans$77K
- Murtuza AliNew Orleans$65K
- Madhur RobertsNew Orleans$28K
- Craig WalkerHouma$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.